Akeso Biopharma’s Cadonilimab Approved for Cervical Cancer Treatment
China-based biotech company Akeso Biopharma (HKG: 9926) announced that its self-discovered bispecific antibody (BsAb) cadonilimab...
Cancer
Kelun Pharmaceutical Receives USD 30 Million from MSD for Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced receiving USD 30 million from...
Antengene and BeiGene Collaborate on Selinexor and Tislelizumab Combination Trial for Lymphoma
China-based Antengene Corporation Ltd (HKG: 6996) has announced a clinical trial collaboration with BeiGene Inc....
Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that the National Medical Products Administration (NMPA)...
Sunshine Guojian Pharmaceutical Signs Licensing Deal for Cipterbin ADC Development
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has...
Jumbo Drug Bank’s JDB153 Enters Phase I Trial for Advanced Solid Tumors
Data from Fineline Cube indicates that JDB153, a potential first-in-class (FIC) small-molecule inhibitor targeting Mnk...
Suzhou Teligene Ltd Plans IPO on Shanghai STAR Market for Cancer Drug Development
China-based Suzhou Teligene Ltd has announced plans for an initial public offering (IPO) of 63.52...
Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial
Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study...
Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share
China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering...
Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment
Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued...
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC...
CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance
China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for...
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801)...
Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion
Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...
Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study
China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...
Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...
Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...
Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...